# US 2025/0145993 A1 · Enhanced expression of alternative spliced uromodulin for therapeuticuse

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145993 A1
- Document ID: US20250145993A1
- Status: Published application
- Kind: A1
- Application number: 18/934,880
- Filed: 2024-11-01
- Published: 2025-05-08
- Earliest claimed: 2023-11-02
- Assignees: The Trustees of Indiana University
- Applicants: The Trustees of Indiana University
- Inventors: Tarek Maurice Ashkar; Azuma Nanamatsu
- Web page: https://patentgrep.com/patent/US20250145993A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 13/12: of the kidneys
- C12N 2310/11: Antisense
- C12N 2310/321: 2'-O-R Modification
- C12N 2320/33: Alteration of splicing
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of enhancing the presence of alternatively-spliced UMOD protein by inducing exon-skipping of a AS-UMOD m-RNA to protect TAL cells of kidneys in a patient suffering from acute kidney injury or chronic kidney disease.

## Claims

### Claim 1

A method of inducing exon-skipping of a AS-UMOD m-RNA in a TAL cell, the method comprising delivering to the cell a splice-switching antisense oligonucleotides (SSO) comprising a sequence selected from the group consisting of SEQ ID NOs: 14, 15, and 16, wherein the antisense oligonucleotide is up to 30 nucleotides in length and is capable of inducing exon-skipping of the UMOD pre-mRNA.

### Claim 2 (depends on 1)

The method of claim 1 wherein the SSO sequence comprises SEQ ID NO: 14.

### Claim 3 (depends on 1)

The method of claim 1 wherein the SSO sequence comprises SEQ ID NO: 15.

### Claim 4 (depends on 1)

The method of claim 1 wherein the SSO sequences comprises SEQ ID NO: 16.

### Claim 5

A method for enhancing endogenous alternatively spliced uromodulin (AS-UMOD) expression in a subject, comprising
administering splice-switching antisense oligonucleotides (SSO) comprising a sequence selected from the group consisting of SEQ ID NOs: 14, 15, and 16 to a subject.

### Claim 6 (depends on 5)

The method of claim 5 wherein the enhanced endogenous AS-UMOD mRNA expression occurs in the kidney of the subject.

### Claim 7 (depends on 5)

The method of claim 5 wherein the enhanced endogenous AS-UMOD mRNA expression occurs in the TAL cells of the subject.

### Claim 8 (depends on 5)

The method of claim 5 wherein the subject is human.

### Claim 9 (depends on 5)

The method of claim 5 wherein the AS-UMOD expressed lacks exon 10.

### Claim 10 (depends on 5)

A method for treating acute kidney injury in a subject using the method of claim 5.

### Claim 11 (depends on 10)

The method of claim 10 wherein the splice-switching antisense oligonucleotides (SSO) is administered to the subject less than 72 hours following acute kidney injury in the subject.

### Claim 12 (depends on 5)

The method of claim 5 wherein the splice-switching antisense oligonucleotides (SSO) is administered to the subject prior to surgery on the kidney of the subject.

### Claim 13 (depends on 5)

The method of claim 5 wherein the splice-switching antisense oligonucleotides (SSO) is administered to the subject less than 72 hours following acute kidney injury in the subject.

### Claim 14 (depends on 5)

The method of claim 5 wherein the SSO is administered to the subject at a dosage of about 2 mg/kg.

### Claim 15

A spice-switching antisense oligonucleotide (SSO) consisting of a sequence that has at least 90% identical over the entire length of SEQ ID NO: 14, 15 or 16.

### Claim 16 (depends on 12)

Method of use of the composition contained the SSO of claim 12 in a subject suffering kidney injury.

### Claim 17

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and two or more antisense oligonucleotides complementary to AS-UMOD, wherein at least one of said antisense oligonucleotides thereof comprises a nucleic acid sequence as set forth in any one of SEQ ID Nos: 14, 15 or 16.
